InvestorsHub Logo

IgnoranceIsBliss

06/07/20 8:09 AM

#278658 RE: MontanaState83 #278657

He said, “would reduce trigs at 400 or 600” NOT “would do it without increasing LDL-C”.

That’s the big leap Du made - saying a POSA would assume no change in LDL-C above that level. Despite all other trig lower drugs working above 500 on TRIGS but raising LDL-C despite doing it while not raising or even lowering LDL-C at lower levels. She said, “No reason to think different re LDL-C.” But there was EVERY reason to think different re LDL-C!

That’s the whole point! Mori, Kurabayashi, Hayashi weren’t relevant because the test populations had moderately high trigs!!!

We have too much time on our hands here. We need to get a hobby while we wait for Singer & Co to do their jobs. Toth conceded nothing of significance in that statement.


HinduKush

06/07/20 9:33 AM

#278664 RE: MontanaState83 #278657

Montana
Not sure what excatly Toth said, without the entire trial transcript in front of me...but having been in the stand myself, I realize what he tried to say , what came out, and what Du understood is the difference betwween dawn an day, dusk and nightfall...
Clarity in the art of examination and cross examination of expert witnesses in science is sometimes less than desired.

HDGabor

06/07/20 12:24 PM

#278708 RE: MontanaState83 #278657

M-

As TTE replied to you it was about TG only.

btw: The TG reduction was obvious ... the USPTO used this(!) for prima facie obviousness ... Meanwhile - If I read correctly - Judge Du referred to USPTO prima facie determination as it was about TG reduction AND LDL-C (non) effect. ...

Best,
G